<DOC>
	<DOCNO>NCT00593177</DOCNO>
	<brief_summary>The primary objective study assess tolerability efficacy 0.10 % 0.05 % PTH ( 1-34 ) parathyroid hormone peptide gel treatment mild moderate plaque psoriasis comparison treatment placebo gel alone .</brief_summary>
	<brief_title>A Safety Efficacy Study Topical Gel Treatment Mild Moderate Psoriasis</brief_title>
	<detailed_description>This pilot study aim confirm result previous proof concept study perform Dr. Michael Holick use different dosage form . The secondary objective determine dose dependent difference trend response two concentration PTH ( 1-34 ) peptide gel . Subjects randomize receive one three treatment group 1:1:1 basis . The three treatment group : - Treatment Group 1 : 0.05 % PTH ( 1-34 ) Gel - Treatment Group 2 : 0.10 % PTH ( 1-34 ) Gel - Treatment Group 3 : Placebo Gel</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Mentally competent complete appropriately administer informed consent . Male nonpregnant female outpatient age 18 65 year . If subject woman childbearing potential , must negative serum pregnancy test screen negative urine pregnancy test baseline , agree use effective , nonprohibited form birth control duration study ( stabilize hormonal contraceptive least two month ( e.g . oral , implant , injection , NuvaRing , patch ) , IUD , condom spermicidal diaphragm spermicidal , abstinence , etc. ) . Willing able apply assign study medication direct , comply study instruction commit followup visit duration study . Clinical diagnosis stable plaque psoriasis least 3 month . Plaque psoriasis minimum 2 % affected BSA ( exclude palm , sol , face , scalp , groin , axillae intertriginous area ) . Subject 's disease suitable manage topically duration trial . Subject Target Plaque must : minimum 16 cm2 area Overall Disease Severity Score 2 3 induration score 2 3 Willing able avoid prolong exposure designate treatment lesion ultraviolet radiation ( natural artificial ) duration study . In good general health free disease state physical condition might impair evaluation plaque psoriasis , investigator 's opinion , expose subject unacceptable risk study participation . Female lactating , plan become pregnant study . Has spontaneously improve rapidly deteriorate plaque psoriasis . Has guttate , pustular , erythrodermic , inverse nonplaque form psoriasis . Has use psoriasis vaccine participate investigational study psoriasis vaccine . Has use systemic immunomodulatory therapy know affect psoriasis DOES typically decrease immune cell population ( e.g . alefacept ) within 36 week prior start treatment . Subject use systemic immunomodulatory therapy know affect psoriasis DOES NOT typically decrease immune cell population ( e.g . efalizumab , etanercept , infliximab , adalimumab , investigational antiTNF antiIL12/23 agent ) within 12 week prior start treatment . Has use phototherapy ( include laser ) , photochemotherapy systemic psoriasis therapy ( e.g . systemic corticosteroid , methotrexate , retinoids cyclosporine ) within 4 week prior start treatment . Prolonged exposure natural artificial source ( e.g . UVB , UVA , etc . ) ultraviolet radiation within 4 week prior start treatment intending exposure study , think investigator likely modify subject 's psoriasis . Has use topical antipsoriatic therapy ( include topical retinoids , corticosteroid , vitamin D derivative , topical immunomodulators , coal tar salicylic acid preparation ) area treat within 2 week prior start treatment . Has use emollients/moisturizers area treat within 2 day prior start treatment . Has use lithium hydroxychloroquine within 4 week prior start treatment . Currently use betablocking medication ( e.g . propranolol ) dose stabilize least 3 month prior start treatment . Has recently medication osteoporosis include limited bisphosphonates , calcitonin , teriparatide , androgen anabolic steroid therapy , fluoride , vitamin D &gt; 50,000 IU/week , within past 6 month . May unreliable include subject engage excessive alcohol intake drug abuse . Subject , opinion investigator , clinically significant abnormality clinical laboratory test ( serum chemistry , hematology urinalysis ) conduct screen . Subject history hypercalcemia ( consistent elevate serum calcium 10.5 mg/dl ) , illnesses affect bone calcium metabolism recent nephrolithiasis urolithiasis ( within previous 2 year ) . Has history radiation therapy involve skeleton . Has history sensitivity ingredient study medication . Currently enrol investigational drug device study . Has use investigational drug investigational device treatment within 30 day prior start treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Plaque psoriasis</keyword>
	<keyword>Psoriasis</keyword>
</DOC>